|
A Patient's Guide to
Managing Hormone-Refractory Prostate Cancer
Chapter 15. Managing
Chemotherapy Side Effects
Introduction
Chemotherapy treatments have many side effects that affect patients in
various degrees. It is important to know that in most cases mitigation of
side effects is possible. Although most side effects caused by chemotherapy
are reversible, it is important to identify the side effects and to consult
your oncologist as soon as possible. Oncology nurses are also a good source
of information about side effect mitigation. They are experienced and
knowledgeable in this process. Side effects such as peripheral neuropathies
can become permanent if not identified early enough. Be perceptive of any
and all changes you perceive as induced by treatment.
For a more complete coverage of side effects and symptoms visit our section
on Side Effects and Symptoms Management.
1. Side effects affecting blood counts
(also see CBC).
Anemia
Anemia is characterized as a reduction of the concentration of
hemoglobin and the circulating red blood cell amounts. A decreased
hemoglobin level, hematocrit value, or RBC count could signify anemia. Such
a condition is associated with cancer and chemotherapy treatments.
Hemoglobin levels can respond to therapy with recombinant human
erythropoietin (hEPO). Procrit, Aranesp and Epogen are commercial names of
forms of erythropoietin. In severe cases of bone marrow depression, blood
transfusions are necessary.
Leukopenia-Granulocytopenia
Leukopenia is characterized as a reduction of circulating white blood
cells (WBC). The reduction is usually reflected by a low count of neutrophil
granulocytes which are the immune system cells that first recognize and
fight infections. Reduced number of these cells can make the patient
susceptible to opportunistic infections. This condition can be severe and
even result in death. Normal signs of infection other than fever might not
be present making this condition a possible silent killer. Neupogen,
Neulasta and Leukine are commercial names of products that stimulate
production of white blood cells.
Thrombocytopenia
A normal platelet count ranges from 150,000 to 350,000 cells/mm3.
Thrombocytopenia is commonly caused by the suppressive effects of
chemotherapy, disease or prior therapy. There is an increasing risk of
bleeding as the platelet count drops. If the platelet count falls to less
than 50,000 cells/mm3 there is a high risk of bleeding. The situation can
become critical at 20,000 cells/mm3 and platelet transfusions are required
at 15,000 cells/mm3 or below.
2. Side effects affecting the gastrointestinal track
Nausea and Vomiting
Two of the most distressing side effects of chemotherapy are nausea and
vomiting. The severity and incidence of these toxicities can vary greatly,
but these symptoms can be bad enough in patients to cause them to stop
treatment.
Some drugs such as Cisplatin and Cyclophosphamide(cytoxan) have a very high incidence
of inducing nausea and vomiting. Carboplatin and Doxorubicin have a high
incidence while Etoposide and Mitoxantrone are moderate inducers. Taxotere,
Taxol and Navelbine are at the lowest rating to induce nausea and vomiting.
This of course varies greatly among patients. Some the latest and most
frequently used antinausea products are: Kytril, Anzamet, Zofran, Aloxi and
Emend.
Anorexia and Taste Changes
Anorexia is the loss of appetite, even to the point of the thought of
food inducing nausea. Anorexia can be induced by chemotherapy or by
anti-pain medications.
Changes in taste sensation and repugnance to certain foods and food odors
can cause a decreased in appetite in the cancer patient. Abnormalities can
include a metallic taste after drug therapy. Remedies include treatment with
steroids and/or dietary supplementation with specially fortified nutritional
products that are commercially available.
Stomatitis
Stomatitis is an inflammation of the lining of any of the soft-tissue
structures of the mouth. Stomatitis is usually a painful condition,
associated with redness, swelling, and occasional bleeding from the affected
area. The cells of the oral mucosa are characterized by their high
proliferating rate. As such they are highly affected by chemotherapy agents.
Oral hygiene is critical in preventing infections. Oral infections can
affect proper nutrition in a cancer patient causing a cascade of side
effects.
Diarrhea and constipation are common side effects of cancer treatment.
Persistent diarrhea can cause dehydration, electrolyte imbalance, weakness,
interference with nutrition and loss of body weight. Constipation, on the
other extreme, can cause cramping, difficult evacuation, feeling of fullness
impacting nutrition and in severe cases intoxication by reabsorption of
toxic waste. Both these conditions must be addressed promptly in the cancer
patient to maintain the proper timing in a chemotherapy schedule. Over the
counter (OTC) medications are widely available to treat these conditions.
3. Side effects affecting the skin or hair
Alopecia or drug induced hair loss is a common side effect of some
chemotherapy drugs and is mostly reversible. Chemotherapy agents most
commonly associated with this side effect are: Cyclophosphamide,
Doxorubicin, Vincristine, Etoposide and the taxanes (taxol and taxotere.)
Systemic dermatologic side effects such as dermatitis, nail changes,
photosensitivity and others are usually limited to the duration of therapy.
Nail lifting or complete loss can be extremely painful and impact quality of
life by limiting patient dexterity in performing daily tasks such as
inserting buttons etc.
4. Toxicity to Other Organ Systems
Chemotherapy induced renal toxicity is related to an alteration in kidney
function. Plasma concentration of blood urea nitrogen (BUN) and creatinine
are commonly used to assess renal function. Cisplatin and Suramin are two
drugs capable of impacting renal function in prostate cancer treatment.
Chemotherapy induced pulmonary toxicity is present when the chemicals affect
lung tissues. The most common toxicities are pneumonitis, pulmonary fibrosis
and pulmonary edema. Symptoms may be acute and cause respiratory distress.
Dypsnea (Shortness of breath or difficulty catching ones breath), cough,
chills, myalgia(Pain in a muscle; or pain in multiple muscles. Myalgia means
muscle pain), fatigue and headache have been reported with chemically
induced pneumonitis. Doxorubicin, Cyclophosphamide and to a lesser amount,
Taxotere, have been reported to induce pulmonary toxicities.
Cyclophosphamide (cytoxan) can cause bladder problems
in the form of hemorrhagic cystitis or scarring.
This is due to a byproduct called acrolein which causes the
irritation. The usual recommendation is to drink a lot of water while taking
it. At high doses of cytoxan, a drug called Mesna(Mesnex) is sometimes
given to help prevent bladder problems.
Cardiac toxicity associated with chemotherapy is mostly related to
anthracycline drugs. Cardiomyopathy(Cardiomyopathy is a serious disease in
which the heart muscle becomes inflamed and doesn't work as well as it
should.) and congestive heart failure are the most commonly reported
carditoxicities. Ischemia, pericarditis(a condition that can cause chest
pain, occurs when the sac that envelops the heart becomes inflamed),
arrhythmia and angina have been reported less frequently. Doxorubicin and
Mitoxantrone are anthracycline drugs known to cause severe cardiotoxicity
with prolonged treatment. Continuous infusions seem to minimize risk. The
drug, zinecard(dexrazoxane), may have some cardioprotective properties.
Toxicity of the central nervous system (CNS). Several chemotherapy drugs can
cause distinct neurologic side effects. Often there is no drug treatment for
these toxicities and sometimes the side effects are irreversible. Peripheral
neuropathies are the most common of these neurological side effects.
Patients should be on guard and alert their oncologists immediately at the
onset of symptoms such as tingling or numbness in hands and feet. Caught
early, there is a better chance of reversing the condition. Peripheral
neuropathy can and does affect quality of life in patients. Visit
pngeneral,
for an excellent review of the topic by Bill Aishman. The drug, ethyol, at
low doses (500mg) may prevent worsening of peripheral neuopathy or possibly
prevent it from developing.
Authors: Ralph Valle and Howard Hansen, 1/23/06
Continue with Chapter 16
|